Grifols Achieves Record Score in 2024 S&P Global Corporate Sustainability Assessment
Grifols Secures 70 Points, Demonstrating a Seven-Point Improvement Over Previous Year
Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a leading global healthcare company and manufacturer of plasma-derived medicines, has announced that it has attained its highest-ever score in the S&P Global ESG evaluation. With a score of 70 points, the company has improved by seven points from last year, showcasing its ongoing dedication to sustainability.
The S&P Global Corporate Sustainability Assessment (CSA) highlighted Grifols’ commitment to human rights, supply chain management, climate change initiatives, and health and safety practices. In the realm of governance, Grifols was recognized for enhancing the responsibility and sustainability of its supply chain, achieving top marks for sustainability reporting and business ethics.
On the environmental front, Grifols has established more ambitious targets to facilitate its transition to a low-carbon economy. S&P acknowledged the company’s advancements in climate strategy while awarding it the highest rating for climate governance and risk management.
In terms of social responsibility, S&P commended Grifols for its dedication to providing a safe and healthy workplace for its employees, along with its commitment to upholding and promoting human rights in all operational areas. The company also received top marks for its ethical marketing practices.
This achievement highlights Grifols’ steadfast commitment to excellence in environmental, social, and governance (ESG) practices. As the company continues to pursue its sustainability objectives, it remains focused on delivering long-term value and making a positive impact toward a more sustainable, ethical, and resilient future for all stakeholders.
For further information on Grifols’ ESG initiatives and progress
